SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., April 22, 2024 — Creyon Bio, Inc. (“Creyon”), a clinical stage biotechnology company engineering and developing Oligonucleotide-Based Medicines (OBMs) for common and rare diseases, today announced that its executives will present and participate in two upcoming medical and industry conferences in May 2024.
SynBioBeta 2024: The Global Synthetic Biology Conference
Date and Time: Wednesday, May 8, 2024, 5:00-5:20 p.m. PT
Location: San Jose, Calif.
Discussion Title: Medicine on Demand: Reimagining Drug Development Through Oligo Innovation
Participant: Christopher Hart, Ph.D., Chief Executive Officer at Creyon Bio
Format: Fireside Chat
American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
Date and Time: Friday, May 10, 2024, 5:15-5:30 p.m. ET
Location: Baltimore, Md.
Abstract Number: 309
Presenter: David Dimmock, M.D., Chief Medical Officer at Creyon Bio
Format: In-Person Oral Presentation
About Creyon Bio, Inc.
Creyon Bio is a clinical stage biotechnology company developing best-in-class precision medicines with industry-leading efficiency through molecular engineering of Oligonucleotide-Based Medicines (OBMs). This includes ASOs, siRNAs, and aptamers. The company is changing how we create novel OBMs, transforming the process from drug discovery to drug engineering. Creyon has built the first and only platform capable of engineering for safety first, establishing industry-leading efficiency for translating new target discoveries to OBMs with optimal pharmacological properties. Coupled with our aptamer-based delivery technologies, Creyon Bio is unlocking the full potential of OBMs for common and rare diseases alike. To learn more, visit creyonbio.com.
Media Contact
Jon Yu